跳至主要内容
临床试验/RBR-6s8qm5
RBR-6s8qm5进行中(未招募)未知

Telephone Assistance and Monitoring for Nausea and Vomiting control associated with outpatient Antineoplastic Chemotherapy

Instituto do Câncer do Ceará0 个研究点开始时间: 2017年9月27日最近更新:

试验速览

阶段
未知
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Intervention

入排标准

年龄范围
— 至 100Y(—)

入选标准

  • Patients aged 18 years and over, patients receiving moderate chemotherapy and high emetogenic potential (intravenous busulfan, carboplatin, combination of doxorubicin or epirubicin with cyclophosphamide, carmustine, cisplatin, intravenous cyclophosphamide, cytarabine (dose> 200mg / m²);Dacarbazine; Dactinomycin; Doxorubicin; Epirubicin (dose> 90 mg / m², ifosfamide (dose> 2 g / m²), mechlorethamine, melphalan, methotrexate (dose> 250 mg / m²), streptozocin, oxaliplatin)

排除标准

  • Cancer of the gastrointestinal tract; Drug therapy with tramadol; Patients who drink alcohol during the treatment period; Patients undergoing daily chemotherapy regimens, these being given individually or in combination therapy, intravenous or oral routes (busulfan, cyclophosphamide, etoposide, procarbazine)

研究者

发起方
Instituto do Câncer do Ceará

相似试验